Literature DB >> 7628047

Antidote studies of vinorelbine-induced skin ulceration in the mouse.

R T Dorr1, K L Bool.   

Abstract

The new cantharanthine-modified vinca alkaloid vinorelbine (Navelbine) was administered intradermally (ID) to dehaired BALB/c mice. Dose-dependent skin lesions were produced over the range 0.01-0.5 mg/mouse, with complete healing after 9-35 days. Local (ID) injections of hydrocortisone and saline were ineffective at blocking vinorelbine-induced skin ulceration. Topical skin heating to 43 degrees C or cooling to 10 degrees C were also ineffective. In contrast, hyaluronidase, 15 Units ID, following vinorelbine significantly reduced skin lesions. These results show that vinorelbine is a vesicant and that inadvertent extravasations may be managed with subcutaneous injection of the spreading factor enzyme, hyaluronidase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628047     DOI: 10.1007/BF00689045

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  VINCRISTINE IN CHILDREN WITH MALIGNANT SOLID TUMORS.

Authors:  D H JAMES; P GEORGE
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

2.  Experimental antitumor activity of Navelbine.

Authors:  S Cros; M Wright; M Morimoto; H Lataste; J P Couzinier; A Krikorian
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

3.  Phase-II study of Navelbine in advanced breast cancer.

Authors:  L Canobbio; F Boccardo; G Pastorino; F Brema; C Martini; M Resasco; L Santi
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

Review 4.  Advances in vinca-alkaloids: Navelbine.

Authors:  M Marty; J M Extra; M Espie; S Leandri; M Besenval; A Krikorian
Journal:  Nouv Rev Fr Hematol       Date:  1989

5.  Inapparent infiltrations associated with vindesine administration.

Authors:  R T Dorr; S E Jones
Journal:  Med Pediatr Oncol       Date:  1979

6.  Phase I pharmacologic study of a new Vinca alkaloid: navelbine.

Authors:  G Mathé; P Reizenstein
Journal:  Cancer Lett       Date:  1985-07       Impact factor: 8.679

7.  Biochemical effects of Navelbine on tubulin and associated proteins.

Authors:  A Fellous; R Ohayon; T Vacassin; S Binet; H Lataste; A Krikorian; J P Couzinier; V Meininger
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

8.  Intravenous vincristine infusion: phase I trial.

Authors:  D V Jackson; V S Sethi; C L Spurr; V Willard; D R White; F Richards; J J Stuart; H B Muss; M R Cooper; H D Homesley; V W Jobson; M C Castle
Journal:  Cancer       Date:  1981-12-15       Impact factor: 6.860

9.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

Authors:  T Le Chevalier; D Brisgand; J Y Douillard; J L Pujol; V Alberola; A Monnier; A Riviere; P Lianes; P Chomy; S Cigolari
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

10.  In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

Authors:  S Binet; A Fellous; H Lataste; A Krikorian; J P Couzinier; V Meininger
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

View more
  1 in total

1.  Rat injury model of docetaxel extravasation.

Authors:  Jing-Jing Zhu; Jian-Fei Fu; Jiao Yang; Bing Hu; Hui Zhang; Jian-Hua Yu
Journal:  Biomed Rep       Date:  2014-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.